KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Common Equity (2016 - 2026)

Esperion Therapeutics filings provide 9 years of Common Equity readings, the most recent being -$302.0 million for Q4 2025.

  • On a quarterly basis, Common Equity rose 22.32% to -$302.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$302.0 million, a 22.32% increase, with the full-year FY2025 number at -$302.0 million, up 22.32% from a year prior.
  • Common Equity hit -$302.0 million in Q4 2025 for Esperion Therapeutics, up from -$451.4 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of -$196.9 million in Q4 2021 to a low of -$455.0 million in Q4 2023.
  • Median Common Equity over the past 5 years was -$336.9 million (2023), compared with a mean of -$343.5 million.
  • Biggest five-year swings in Common Equity: plummeted 4148.05% in 2021 and later increased 22.32% in 2025.
  • Esperion Therapeutics' Common Equity stood at -$196.9 million in 2021, then crashed by 64.4% to -$323.8 million in 2022, then plummeted by 40.53% to -$455.0 million in 2023, then grew by 14.57% to -$388.7 million in 2024, then rose by 22.32% to -$302.0 million in 2025.
  • The last three reported values for Common Equity were -$302.0 million (Q4 2025), -$451.4 million (Q3 2025), and -$433.5 million (Q2 2025) per Business Quant data.